Vanguard Group’s Agile Therapeutics AGRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | – | Sell |
-20,477
| Closed | -$39.9K | – | 4556 |
|
|
2023
Q4 | $39.9K | Buy |
+20,477
| New | +$41.2K | ﹤0.01% | 4386 |
|
|
2023
Q2 | – | Sell |
-1,537
| Closed | -$17.2K | – | 4629 |
|
|
2023
Q1 | $17.2K | Hold |
1,537
| – | – | ﹤0.01% | 4533 |
|
|
2022
Q4 | $17.4K | Buy |
1,537
+949
| +161% | +$11K | ﹤0.01% | 4500 |
|
|
2022
Q3 | $9K | Sell |
588
-14
| -2% | -$344 | ﹤0.01% | 4599 |
|
|
2022
Q2 | $35K | Sell |
602
-1,337
| -69% | -$194K | ﹤0.01% | 4600 |
|
|
2022
Q1 | $812K | Sell |
1,939
-308
| -14% | -$197K | ﹤0.01% | 4273 |
|
|
2021
Q4 | $2.19M | Buy |
2,247
+195
| +10% | +$275K | ﹤0.01% | 4000 |
|
|
2021
Q3 | $3.95M | Hold |
2,052
| – | – | ﹤0.01% | 3794 |
|
|
2021
Q2 | $5.46M | Sell |
2,052
-137
| -6% | -$452K | ﹤0.01% | 3546 |
|
|
2021
Q1 | $9.11M | Buy |
2,189
+3
| +0.1% | +$16.2K | ﹤0.01% | 3200 |
|
|
2020
Q4 | $12.6M | Buy |
2,186
+279
| +15% | +$1.64M | ﹤0.01% | 2875 |
|
|
2020
Q3 | $11.6M | Sell |
1,907
-49
| -3% | -$281K | ﹤0.01% | 2713 |
|
|
2020
Q2 | $10.9M | Buy |
1,956
+253
| +15% | +$1.31M | ﹤0.01% | 2728 |
|
|
2020
Q1 | $6.34M | Buy |
1,703
+398
| +30% | +$2.28M | ﹤0.01% | 2846 |
|
|
2019
Q4 | $6.53M | Buy |
1,305
+144
| +12% | +$503K | ﹤0.01% | 3070 |
|
|
2019
Q3 | $2.75M | Buy |
1,161
+295
| +34% | +$727K | ﹤0.01% | 3340 |
|
|
2019
Q2 | $2.53M | Buy |
866
+489
| +130% | +$1.37M | ﹤0.01% | 3403 |
|
|
2019
Q1 | $1.14M | Buy |
377
+27
| +8% | +$57.2K | ﹤0.01% | 3592 |
|
|
2018
Q4 | $404K | Sell |
350
-197
| -36% | -$302K | ﹤0.01% | 3776 |
|
|
2018
Q3 | $401K | Buy |
547
+6
| +1% | +$4.39K | ﹤0.01% | 3887 |
|
|
2018
Q2 | $534K | Buy |
541
+25
| +5% | +$87.7K | ﹤0.01% | 3814 |
|
|
2018
Q1 | $2.65M | Buy |
516
+20
| +4% | +$132K | ﹤0.01% | 3364 |
|
|
2017
Q4 | $2.67M | Buy |
496
+161
| +48% | +$1.5M | ﹤0.01% | 3335 |
|
|
2017
Q3 | $2.99M | Buy |
335
+68
| +25% | +$522K | ﹤0.01% | 3287 |
|
|
2017
Q2 | $2M | Sell |
267
-134
| -33% | -$927K | ﹤0.01% | 3380 |
|
|
2017
Q1 | $2.57M | Buy |
401
+178
| +80% | +$895K | ﹤0.01% | 3299 |
|
|
2016
Q4 | $2.54M | Buy |
223
+19
| +9% | +$266K | ﹤0.01% | 3282 |
|
|
2016
Q3 | $2.85M | Buy |
204
+16
| +9% | +$228K | ﹤0.01% | 3256 |
|
|
2016
Q2 | $2.87M | Buy |
188
+1
| +0.5% | +$13.7K | ﹤0.01% | 3230 |
|
|
2016
Q1 | $2.33M | Buy |
187
+118
| +171% | +$1.52M | ﹤0.01% | 3317 |
|
|
2015
Q4 | $1.35M | Buy |
69
+12
| +21% | +$190K | ﹤0.01% | 3534 |
|
|
2015
Q3 | $774K | Buy |
57
+22
| +63% | +$391K | ﹤0.01% | 3713 |
|
|
2015
Q2 | $606K | Buy |
35
+21
| +150% | +$448K | ﹤0.01% | 3813 |
|
|
2015
Q1 | $258K | Buy |
14
+4
| +40% | +$70.1K | ﹤0.01% | 3957 |
|
|
2014
Q4 | $119K | Buy |
+10
| New | +$127K | ﹤0.01% | 3967 |
|
Other funds holding AGRX
Vanguard Group's AGRX Position: Q1 2024 in Review
Vanguard Group sold out of Agile Therapeutics (AGRX) in Q1 2024, closing a stake of 20,477 shares — an estimated $39.9K sold.
Vanguard Group first reported a position in AGRX in Q4 2014 and held it in 35 quarters. The position peaked at $12.6M in Q4 2020. 1 fund tracked by Wall St. Rank holds AGRX as of Q1 2024.
- Vanguard Group reported no remaining Agile Therapeutics position as of Q1 2024 after selling out during the quarter.
- Vanguard Group sold 20,477 Agile Therapeutics shares in Q1 2024, an estimated $39.9K.
- Vanguard Group first reported a position in Agile Therapeutics in Q4 2014 and held it in 35 quarters.
- Vanguard Group's Agile Therapeutics position peaked at $12.6M in Q4 2020.
- 1 fund tracked by Wall St. Rank held Agile Therapeutics as of Q1 2024.
Based on Vanguard Group's 13F filing for Q1 2024, filed 10 May 2024.